In Court
Ranbaxy barred
Ranbaxy in a spot
Sun Pharma to buy troubled giant Ranbaxy
The combined entity will create India’s largest pharma company and world’s fifth-largest specialty generics company
Sun-Ranbaxy merger: CCI says deal may hurt competition, seeks public opinion
The merger would lead to creation of the world's fifth-largest maker of generic drugs
Ranbaxy effect: Indian government defends pharma industry
Few isolated cases cannot undermine well regulated system, says commerce ministry
SC issues notice to Ranbaxy on allegation of selling poor quality drugs
Petition seeks sealing of all manufacturing units of pharma major
The world needs pharmaceuticals from China and India to beat COVID-19
Chinese manufacturers make around 40% of all APIs used worldwide; China, India are the source of 75-80% of APIs imported to US
Sun Pharma recalls 200 cancer drug vials from US
Second such recall this year by pharma giant that acquired Ranbaxy earlier this year
Ranbaxy to pay $500 million to settle cases in US
Company was selling sub-standard drugs; submitted false claims to health authorities
EU fines nine pharma companies for violating competition rules
Lundbeck pharma made other companies enter market late with generic versions of its drug citalopram
Ranbaxy launches new anti-malarial drug
It has an efficacy rate of over 95 per cent, claims company
Substantiate allegations against Ranbaxy, says Supreme Court
Experts say allegations against the generic pharma company motivated by vested interests
Novartis loses patent appeal in landmark suit
Supreme Court upholds amended law that bars patents for insignificant improvements to an existing drug—in this case anti-cancer drug …